CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 149 enrolled
Drug / intervention
TJ0113 200mg +2 moredrug
Likely dose
TJ0113 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06596005
NCT06596005Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsule in Patients With Early-stage Parkinson's Disease

Second Affiliated Hospital, School of Medicine, Zhejiang University·interventional·Posted Sep 19, 2024·Updated Jan 16, 2026

In Brief

A Phase 2 clinical trial evaluating TJ0113 200mg, TJ0113 400mg, and 1 other intervention for Parkinson Disease. Completed, enrolled 149 participants across 1 site.

Detailed Summary

A randomized, double-blind, placebo parallel-controlled Phase II clinical trial to evaluate the efficacy and safety of TJ0113 capsule in patients with early-stage Parkinson's disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesChina
CollaboratorsTaizhou Hospital, Wenzhou Central Hospital, Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Jiaxing University, Hangzhou PhecdaMed Co., Ltd., Huzhou Central Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Timeline

Phase 2CompletedFinished
20252026
First PostedSep 19, 2024
Enrollment StartSep 18, 2024
Primary CompletionSep 3, 2025
Study CompletionSep 9, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 1.8 years ago

Interventions

TJ0113 200mgdrug

200 mg Capsule, Once Daily

TJ0113 400mgdrug

400 mg Capsule, Once Daily

Placebodrug

Capsule, Once Daily